Perspective Therapeutics Inc (CATX)

[nbm16yankees]

IsoRay (ISR) Results 'Exceptional', Maxim Group Says; Reiterates Buy Rating, $5 PT
1:58 PM ET, 05/20/2015 - StreetInsider
Maxim Group analyst Jason Kolbert reiterated a Buy rating and $5 price target on IsoRay, Inc. (NYSE: ISR) announced the on-line publication of the first major peer reviewed study showing improved results using IsoRay's Cesium-131 seeds in the treatment of lung cancer. Cesium-131 showed 96% success in local control and 100% survival at 5 years in high risk patients.
Kolbert commented, "We believe Cs-131 is a more efficacious, safer alternative to the SOC isotopes Iodine-125 or Palladium-103. Cs-131 hits the tumor faster and harder (shorter half life) which should convince physicians to adopt. As Cs-131 is now in centers in the east, west and central parts of the US, we believe adoption will continue. More data and more publications are coming to help the push."